Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...
A review in Glycoscience & Therapy summarizes advances in selective editing of N-glycan signals on living cell surface via the LCS‑NGS technology platform. It focuses on enzyme‑based strategies ...
The new method relies on methyl groups, small chemical tags attached to DNA that regulate whether genes are on or off. This ...
Morning Overview on MSN
Study finds blocking GCN1 boosts T cells’ cancer-fighting power
A protein that helps cancer cells hide from the immune system may have a critical weakness, according to research that could ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Living cell surface N-glycans act as a "glycan code" that mediates cell–cell communication, immune recognition, and disease progression. Unlike ...
Cells constantly probe their environments, searching for physical cues that guide their behavior. And yet a cell's response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results